BioSpace News Archive

Now, with the newly FDA-cleared Compressed SPEEDER technology for Canon Medical Systems USA, Inc.’s Vantage Orian 1.5T MR system, clinicians can speed up MRI scan times by reconstructing full resolution images from under-sampled data through iterative reconstruction

Teva to Present New Data on AJOVY ® (fremanezumab-vfrm) Injection Open-Label Extension Study at American Headache Society Annual Meeting

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Ray Jordan has joined Moderna as Chief Corporate Affairs Officer, effective Monday, June 15, 2020.

JUVÉDERM® VOLUMA™ XC IS FIRST AND ONLY PRODUCT OF ITS KIND APPROVED BY THE FDA FOR USE IN THE CHIN [15-June-2020] IRVINE, Calif. , June 15, 2020 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the FDA approval of JUVÉDERM ® VOLUMA ™ XC for the augmentation of the chin region to improve the chin profile in adults over the age

Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the appointment of Dr. Kira Sheinerman as the senior strategic consultant based in New York effective immediately. “We are really excited to welcome Dr. Sheinerman to the team,” said Mr. Ian Huen, CEO and Executive Director of Aptorum Group. “Dr. Sheinerman

Hua Medicine, a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, announced post-analysis results from dorzagliatin’s 24-week monotherapy trial SEED,.

AVITA Medical Limited ACN 058 466 523 is pleased to announce that shareholders voted in favour of the scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries from Australia to the United States of America, under which AVITA Therapeutics, Inc., a company incorporated in the State of Delaware in the United States of America, will become the parent company of the Avita Group.

Nanoform Finland Plc announced the appointment of Peter Hänninen as General Counsel, effective as of September 1, 2020.

Epsilen Bio, a biotechnology company developing transformative therapies for patients affected by underserved medical conditions through stable epigenetic silencing of genes involved in pathological processes, announced the appointments of Julia Berretta, Ph.D, as Chief Executive Officer, and Mathieu Simon, M.D., as Chairman of the Board.

Oncopeptides AB announces that the full top-line results from the pivotal phase 2 HORIZON study, evaluating intravenous melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma, have been presented at the ongoing 25th European Hematology Association meeting, EHA.